摘要
目的 建立高效液相色谱-串联质谱(LC-MS/MS)测定人尿中匹诺塞林浓度,考察其在中国健康受试者尿液中的排泄特征。方法 尿样用乙醚液-液萃取,采用LunaTMC8色谱柱(2.00 mm×150 mm,3 μm)分离,以乙腈-0.3 mmolL-1醋酸铵水溶液(65∶35, V/V)为流动相进行等度洗脱,流速为0.25 mLmin-1,通过电喷雾离子源(ESI),多重反应监测(MRM)负离子模式进行检测。8名受试者静脉滴注匹诺塞林40 mg,测定匹诺塞林的尿药排泄参数。结果 匹诺塞林在3~200 ngmL-1内线性关系良好,定量下限为3 ngmL-1,批内、批间变异(RSD)小于6.34%,稳定性较好。受试者给药后,匹诺塞林在给药结束后4 h尿的累积排泄百分率达到平台,48 h累计排泄百分率为(0.11±0.05)%。结论 该方法快速、灵敏、准确、专属性强、重现性高,适用于人尿中匹诺塞林的测定及其尿药排泄特征研究。
Abstract
OBJECTIVE To develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determination of pinocembrin in human urine, and to investigate its urinary excretory after intravenous drip administration of pinocembrin in healthy volunteers. METHODS The urine samples were extracted with ether. The separation was performed on a Luna C8 column (2.00 mm×150 mm, 3 μm) using the mobile phase composed of acetonitrile-0.3 mmolL-1 ammonium acetate solution (65∶35, V/V) at a flow rate of 0.25 mLmin-1 in isocratic mode. The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) via electrospray ionization (ESI) source in negative mode. Urinary excretion parameters were calculated after a single intravenous drip administration of pinocembrin at 40 mg to humans. RESUTLS The assay was linear from 3 ngmL-1 to 200 ngmL-1, with the lower limit of quantification at 3 ngmL-1. The within-run and between-run precision (RSD) were below 6.34%. Pinocembrin had good stability. At 4 h after the completion of administration, the urinary cumulative excretion percentage reached a plateau and the cumulative excretion percentage in urine within 48 h were (0.11±0.05) %. CONCLUSION This method is rapid,sensitive, accurate, specific and reliable, and suitable for the determination of pinocembrin in human urine and for the investigation to the urinary excretion.
关键词
高效液相色谱-串联质谱法 /
匹诺塞林 /
尿药排泄
{{custom_keyword}} /
Key words
LC-MS/MS /
pinocembrin /
urinary excretion
{{custom_keyword}} /
严蓓,曹国颖,闫记灵,胡欣,彭悦颖,边子睿,李可欣*.
LC-MS/MS测定人尿中匹诺塞林浓度及尿排泄研究[J]. 中国药学杂志, 2014, 49(17): 1540-1544 https://doi.org/10.11669/cpj.2014.17.015
YAN Bei, CAO Guo-ying, YAN Ji-ling, HU Xin, PENG Yue-ying, BIAN Zi-rui, LI Ke-xin*.
Determination of Pinocembrin in Human Urine by LC-MS/MS and Research on Urinary Excretion[J]. Chinese Pharmaceutical Journal, 2014, 49(17): 1540-1544 https://doi.org/10.11669/cpj.2014.17.015
中图分类号:
R285.5
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LIU R,GAO M,YANG Z H, et al.Pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro [J].Brain Res, 2008, 1216:104-115.[2] GAO M,ZHU S Y,TAN C B, et al. Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats [J]. J Asian Nat Prod Res, 2010, 12 (5):407-418.[3] MENG F,LIU R,GAO M, et al.Pinocembrin attenuates blood-brain barrier injury induced by global cerebral ischemia-reperfusion in rats [J].Brain Res, 2011, 1391:93-101.[4] SHI L L,QIANG G F,GAO M, et al. Effect of pinocembrin on brain mitochondrial respiratory function[J].Acta Pharm Sin(药学学报), 2011, 46(6):642-649.[5] GARDANA C, SIMONETTI P,BERTI C, et al. Evaluation of propolis polyphenols absorption in humans by liquid chromatography/tandem mass spectrometry [J]. Rapid Commun Mass Spectrom, 2007, 21(23):3849-3854.[6] CFDA. Guidance for the clinical pharmacokinetics of chemical drugs[S].2005.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家科技部“重大新药创制”科技重大专项(2012ZX09303008-002);国家自然科学基金资助项目(81202601)
{{custom_fund}}